Dosage regimen optimization in cancer chemotherapy using a mathematical model;Optimisation de la posologie et des modalités d'administration des agents cytotoxiques à l'aide d'un modèle mathématique

Bulletin du Cancer

Volumn 90, Issue 2, 2003, Pages 167-175

  Barbolosi, Dominique ^a,b   Freyer, Gilles ^c   Ciccolini, Joseph ^a   Iliadis, Athanassios ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b Fac des Sci et Techniques   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Chemotherapy; Mathematical modeling; Optimization

Indexed keywords

ANTINEOPLASTIC AGENT; ETOPOSIDE;

ARTICLE; CANCER CHEMOTHERAPY; COMPARATIVE STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INFUSION; DRUG MEGADOSE; FEASIBILITY STUDY; LEUKOCYTE; LEUKOPENIA; MAINTENANCE THERAPY; MATHEMATICAL MODEL; SIMULATION;

ANTINEOPLASTIC AGENTS; LEUKOPENIA; MODELS, CHEMICAL; NEOPLASMS;

EID: 0037301021     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Swan GW, Vincent TL. Optimal control analysis in the chemotherapy of IgG multiple myeloma. Bull Math Biol 1977 ; 39 : 317-37.
2. Swan GW. Applications of optimal control theory in biomedicine. Marcel Dekker, New York 1984.
3. Swan GW. Role of optimal control theory in cancer chemotherapy. Math Biosci 1990 ; 101 : 237-84.
4. Iliadis A, Barbolosi D. Optimizing drug regimens in cancer chemotherapy by an efficacy-toxicity mathematical model. Comput Biomed Res 2000 ; 33 : 211-26.
5. Saijo N. Chemotherapy: The more the better ? Overview. Cancer Chemother Pharmacol 1997 ; 40 : S100-6.
6. Peters WP, Dansey R. New concepts in the treatment of breast cancer using high-dose chemotherapy. Cancer Chemother Pharmacol 1997 ; 40 : S88-S93.
7. Ratain MJ, Schilsky RL, Conley BA, Egorin MJ. Pharmacodynamics in cancer therapy. J Clin Oncol 1990 ; 8 : 1739-53.
8. DeVita VT. Principles of chemotherapy, in: DeVita VT, Hellman S, Rosenberg SA (eds). Principles and practice in oncology. Lippincotr, Philadelphia, 1985 p 257-85.
9. Seber GAF, Wild CJ. Nonlinear regression analysis. John Wiley, New York 1989.
10. Collins JM, Zaharko DS, Dedrick RL, Chabner BA. Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep 1986 ; 70 : 73-80.
11. Mick R, Ratain MJ. Statistical approaches to pharmacodynamic modeling: motivations, methods, and misperceprions. Cancer Chemother Pharmacol 1993 ; 33 : 1-9.
12. Clark PI, Slevin ML, Joel SP, Osborne RJ, Talbot DI, Johnson PWM, Reznek R, Masud T, Gregory W, Wrigley PFM. A randomized trial of two etoposide schedules in small-lung cancer: The influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol 1994 ; 12 : 1427-35.
13. Stewart CF, Arbuck SG, Fleming RA, Evans WE. Relation of systemic exposure to unbound etoposide and hematologic toxicity. Clin Pharmacol Therap 1991 ; 50 : 385-93.
14. Sundareshan MK, Fundakowski RS. Periodic optimization of a class of bilinear systems with application to control of cell proliferation and cancer therapy. IEEE Transactions on Systems, Man, and Cybernetics 1985 ; 15 : 102-15.
15. Murray JM. Some optimal control problems in cancer chemotherapy with a toxicity limit. Math Biosci 1990 ; 100 : 49-67.
16. Murray JM. Optimal control for a cancer chemotherapy problem with general growth and loss functions. Math Biosci 1990 ; 13 : 437-45.
17. Martin RB, Fisher ME, Minchin RF, Teo KL. Low-intensity combination chemotherapy maximizes host survival time for tumors drug-resistant cells. Math Biosci 1992 ; 110 : 221-52.
18. Coldman AJ, Goldie JH. A model for the resisrance of tumor cells to cancer chemotherapeutic agents. Math Biosci 1983 ; 65 : 291-307.
19. Joel SP, Shah R, Slevin ML. Eroposide dosage and pharmacodynamics. Cancer Chemother Pharmacol 1994 ; 34 : S69-S75.
20. Stewart CF. Use of etoposide in patients with organ dysfunction: Phatmacokinetic and phatmacodynamic considerations. Cancer Chemother Pharmacol 1994 ; 34 : S76-S83.
21. Slevin ML, Clark PI, Joel SP. A randomnized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 1989 ; 7 : 1333-40.
22. Thompson DS, Hainsworth JD, Hande KR, Holzmer MC, Greco FA. Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: A phase I-II study. J Clin Oncol 1993 ; 11 : 1322-8.
23. Katlsson MO, Port RE, Ratain MJ, Sheinet LB. A population model for the leukopenic effect of etoposide. Clin Pharmacol Therap 1995 ; 57 : 325-34.